Global Next-Generation Antibody Therapeutics Market Analysis and Forecast Report 2030

$5,000$10,000

Global Next-Generation Antibody Therapeutics Market: Market Segments: By Therapeutic Area (Oncology Autoimmune/Inflammatory); By Technology (Antibody-Drug Conjugates (ADCs), Bispecific Antibodies, Fc-engineered Antibodies, Antibody Fragments and Antibody-like Proteins & Biosimilar Antibody Products);and Region – Analysis of Market Size, Share & Trends for 2014 – 2019 and Forecasts to 2030

Clear

Description

Global Next-Generation Antibody Therapeutics Market Analysis and Forecast Report 2030

Product Overview
Use of a new improvised therapeutic antibody to form novel medicines for the treatment of different diseases includes next-generation antibody therapeutics. Next-generation antibody therapeutics have been clinically developed for many diseases by pharmaceutical and biotechnology firms. Next-generation antibody-based therapeutics for the treatment of different medical conditions such as cancer, infectious diseases, and autoimmune diseases improve the current properties of therapeutic antibodies. For the reason of their unique pharmacological characteristics, the science and development involved in the production of next-generation antibodies generate great interest for many biotech and pharmaceutical companies, increase specificity for established cell types, and low intrinsic toxicity. Sacituzumab govitecan, an antibody-drug conjugate (ADC) composed of a humanized anti-Trop-2 antibody conjugated to SN38 is studied for the treatment of patients with metastatic triple-negative breast cancer. Immunomedics, a pharmaceutical company focusing on the development of antibody-drug conjugates for the treatment of cancer is planning clinical studies of the ADC in other cancers.

Market Highlights
Global next-generation antibody therapeutics market to surpass USD 14.26 million by 2030 from USD 4.69 million in 2019 at a CAGR of 13.69% throughout the forecast period, i.e. 2019-30.
The worldwide increase in the occurrence of different chronic diseases, the increase in the use of therapeutic antibodies, the production and invention of new medicines, and the increase in research and development activities for the preparation of new therapies are the key factors that are fueling the worldwide rise in the demand for next-generation antibody therapeutics.

Global Next-Generation Antibody Therapeutics Market: Segments
Oncology Segment to grow with the highest CAGR of XX.X% during 2019-30
Global Next-Generation Antibody Therapeutics Market is segmented by therapeutic area into oncology and autoimmune/inflammatory. The greater market share in 2019 was accounted for by the oncology segment and is expected to see the highest growth during the forecast period due to the rising incidence of cancer globally. The key factors for market growth are the growing prevalence of cancer worldwide, where next-generation antibodies serve as the predominant therapy and new product launches.

Antibody-Drug Conjugates segment to grow with the highest CAGR of XX.X% during 2019-30
Global Next-Generation Antibody Therapeutics Market is segmented by technology into Antibody-Drug Conjugates (ADCs), Bispecific Antibodies, Fc-engineered Antibodies, Antibody Fragments and Antibody-like Proteins, Biosimilar Antibody Products. The greater market share in 2019 was accounted for by ADCs and is estimated to dominate during the forecast period. One of the major developments in the next-generation antibody therapeutics market is the progress in ADC technology. The ADC technology combines the cytotoxic potential of chemotherapy and advantageous characteristics of antibodies, which leads to high specificity and efficiency of ADCs.

Global Next-Generation Antibody Therapeutics Market: Market Dynamics
Drivers
Increasing investments in healthcare infrastructural development
During the forecast period, the global next-generation demand for antibody therapeutics is likely to expand at a significant rate. This is largely due to the success of antibody therapeutics for chronic conditions such as cancer and autoimmune diseases of the next generation. Generally speaking, antibody therapeutics have experienced clear scientific developments to improve their effectiveness. Also, due to technological developments in antibody therapeutics and increasing the prevalence of chronic diseases, the market is experiencing substantial growth. Moreover, the growth of the next-generation antibody therapeutics market is driven by increasing healthcare expenditure and growing R&D activities.

Increasing volume of chronic patients
A significant factor in boosting the market for next-generation antibody therapeutics would also be the rising prevalence of chronic disorders. Also, the introduction of technology to support R&D activities is another key factor anticipated to drive the growth of the industry over the next few years. In the antibody therapeutics market, many governments are growing funding and grants for research activities. This, combined with rising spending on healthcare by both developed and developing countries, would also drive demand growth during the forecast period.

Restraints
High cost involved in research and development for developing next-generation antibodies
Different governments have implemented numerous stringent rules and regulations relating to the use of antibodies, which are significantly hampering the global demand for next-generation antibody therapeutics. Also, the high investment required for R&D activities and the preference among medical and healthcare professionals as well as patients for older-generation drug therapies are some of the major issues facing the global market during the forecast period.

Global Next-Generation Antibody Therapeutics Market: Regions
Global next-generation antibody therapeutics market is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, APAC, and MENA. Global next-generation antibody therapeutics market in North America held the largest market share of XX.X% in the year 2019 and due to growing R&D activities, technical advancements in antibody therapies, growing healthcare expenditure, and increasing government initiatives in this area, growth over the forecast period is expected to be sustained. Also, the growth of the market is driven by the growing prevalence of chronic diseases and by the growing approval of new medicines. It is anticipated that the growing occurrence of multiple diseases, growing advances in therapeutic antibodies, evolving antibody technologies, rising demand for better healthcare services, and rapid growth in biosimilar antibodies and engineered antibodies will bring new opportunities for the region’s next-generation therapeutic antibody industry.

Global next-generation antibody therapeutics market is further segmented by region into:
North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
APAC Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
Row Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA
Global Next-Generation Antibody Therapeutics Market: Recent Development
In June 2019, Xencor has initiated the first dose in patients in phase I clinical trial for XmAb22841, a bispecific antibody that targets CTLA-4 and LAG-3 receptor inhibitors for the treatment of advanced solid tumors. If successful, it will change the treatment landscape of patients suffering from advanced solid tumors throughout the world
In December 2018, Seattle Genetics, Inc in collaboration with Takeda Pharmaceutical Company Limited has reported in the press release that the ECHELON-2 phase III clinical trial demonstrated clinically meaningful outcomes of brentuximab vedotin in combination with CHP (cyclophosphamide, doxorubicin, and prednisone) for the treatment of CD30-Expressing Peripheral T-cell lymphomas. If SUCCESSFUL, it will bring a potential new treatment option to patients suffering from peripheral T-cell lymphomas across the globe.
Global Next-Generation Antibody Therapeutics Market: Key Players
Bristol-Myers Squibb
Company Overview
Business Strategy
Key Product Offerings
Financial Performance
Key Performance Indicators
Risk Analysis
Recent Development
Regional Presence
SWOT Analysis
Pfizer
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Bayer
Takeda Pharmaceuticals
Biogen
Seattle Genetics
ImmunoGen
Kyowa Hakko Kirin
Xencor
Dyax Corp
Global Next-Generation Antibody Therapeutics Market report also contains analysis on:
Global next-generation antibody therapeutics market Segments:

By Therapeutic Area:
Oncology
Autoimmune/Inflammatory
By Technology:
Antibody-Drug Conjugates (ADCs)
Bispecific Antibodies
Fc-engineered Antibodies
Antibody Fragments and Antibody-like Proteins
Biosimilar Antibody Products
Next-generation antibody therapeutics Market Dynamics
Next-generation antibody therapeutics Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints

Additional information

Publisher

Geography Covered

Date Published

,

Pages

Format

Table of Contents

Contents
1. Executive Summary
2. Global Next-Generation Antibody Therapeutics Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. Average Pricing Analysis
5. Macro-Economic Indicators
6. Market Dynamics
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. Correlation & Regression Analysis
7.1. Correlation Matrix
7.2. Regression Matrix
8. Recent Development, Policies & Regulatory Landscape
9. Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. Global Next-Generation Antibody Therapeutics Market Analysis
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. Global Next-Generation Antibody Therapeutics Market
11.1. Market Size & forecast, 2019A-2030F
11.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.2. By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12. Global Next-Generation Antibody Therapeutics Market: Market Segmentation
12.1. By Regions
12.1.1. North America: (U.S. and Canada) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2. By Technology: Market Share (2020-2030F)
13. 12.3.1. Antibody-Drug Conjugates (ADCs), By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
14. 12.3.2. Bispecific Antibodies, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
15. 12.3.3. Antibody Fragments and Antibody-like Proteins, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
16. 12.3.4. Fc-engineered Antibodies, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
17. 12.3.5. Biosimilar Antibody Products, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
18. Company Profile
18.1. Hoffmann-La Roche Ltd.
18.1.1. Company Overview
18.1.2. Company Total Revenue (Financials)
18.1.3. Market Potential
18.1.4. Global Presence
18.1.5. Key Performance Indicators
18.1.6. SWOT Analysis
18.1.7. Product Launch
18.2. Kyowa Hakko Kirin Co. Ltd.
18.3. Seattle Genetics Inc.
18.4. ImmunoGen Inc.
18.5. Bristol-Myers Squibb Company
18.6. Pfizer Inc.
18.7. Amgen Inc
18.8. Biogen
18.9. Xencor Inc
18.10. Other Prominent Players
19. Consultant Recommendation
**The above-given segmentation and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.

Reviews

There are no reviews yet.

Be the first to review “Global Next-Generation Antibody Therapeutics Market Analysis and Forecast Report 2030”